Coronavirus Update: Gilead's Veklury Gets Full FDA Approval, Roche Partners With Atea
Moderna Fully Enrolls COVE Trial
Executive Summary
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
You may also be interested in...
Coronavirus Update: With New Data, Don’t Count J&J Out Yet
J&J announced strong data for its single-shot vaccine, with even stronger booster shot data to boot. Also Gilead posted strong results for outpatient use of Veklury, but it faces stiff competition, while Clover announced new data and Pfizer/BioNTech sold another 500 million vaccine doses for donation.
Pandemic Perspectives: Remdesivir, Favipiravir’s Eventful Journeys In India A Year On
COVID-19 doesn't seem to be going away any time soon and antivirals remdesivir and favipiravir remain part of the treatment armamentarium. “Safety inventories” are in place for remdesivir in India, while a key physician anticipates an uptick in the use of favipiravir amid a surge in cases in some parts of the country.
In Vivo’s Deals Of The Year 2020: Cast Your Vote!
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.